Infergen interferon alfacon-1: Marketed

In a study of 554 patients with chronic HCV who had relapsed or had not responded following treatment with the combination of Schering-Plough Corp.'s Intron A interferon alfa-2b and ribavirin, 77 percent and 83 percent of relapse patients who received 9 ug/day or 15 ug three times per week of Infergen, respectively, were HCV negative after 48 weeks. In the non-responder group at 48 weeks, 40 percent and 16 percent of patients in the 9 ug/day and 15 ug three times per week groups, respectively, were HCV negative. ...